Results 11 to 20 of about 65,592 (243)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization

Cancer Medicine, 2023
Background The efficacy‐effectiveness gap between randomized trial and real‐world evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has been well characterized by previous literature, consistent with initial concerns ...
Brandon Lu, Wei Fang Dai, Ruth Croxford, Wanrudee Isaranuwatchai, Jaclyn Beca, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Rebecca E. Mercer, Timothy P. Hanna, Kelvin K. W. Chan   +12 more
doaj   +1 more source

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

World Journal of Surgical Oncology, 2020
Background Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer ...
Jingjie Chen, Shengnan Li, Qigu Yao, Nannan Du, Xiaojun Fu, Yuanmei Lou, Mengru Wang, Feiyan Mao, Danyi Mao, Parikshit Asutosh Khadaroo, Yingying Tang   +10 more
doaj   +1 more source

Ipilimumab [PDF]

Drugs in R&D, 2010
Ipilimumab (BMS734016; MDX 101; MDX-010; MDX-CTLA-4; MDX-CTLA4) is an anti-CTLA-4 monoclonal antibody, which is in development by Medarex Inc. and Bristol-Myers Squibb as treatment for malignant melanoma, prostate cancer, lymphoma, and lung cancer. It is currently in phase III development for the melanoma and prostate cancer indications, and phase II ...
openaire   +2 more sources

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source

Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases [PDF]

, 2018
Purpose: We performed a phase I study to determine the maximum tolerable dose (MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Andrews MD, David W., Daskalakis, Constantine, Dicker, Adam, MD, PhD, Eldredge-Hindy, Harriet B., Evans, James J., Farrell, MD, Christopher J, Feeney, Kendra J., Garg, Shivank, Judy, MD, Kevin, Kendra, Kari L., Kim, Lyndon, Kim, MD, Hyun, Liebner, David A., Mastrangelo, Michael, Olencki, Thomas, Palmer, Joshua D., Sato, Takami, Shi, Wenyin, Werner-Wasik, Maria, Williams, Noelle L., Wuthrick, Evan J.   +20 more
core   +2 more sources

Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports [PDF]

, 2014
Ipilimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte antigen4 (CTLA-4), an inhibitory molecule typically expressed on T cells. Blockade of CTLA-4 induces an overall activation of T cells, including an immune-mediated anti-tumour ...
Brochez, Lieve, Cocquyt, Veronique, KRUSE, VIBEKE, Marlier, Joke, Van Belle, Simon   +4 more
core   +2 more sources

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

BMC Cancer, 2020
Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness.
Wei Fang Dai, Jaclyn M. Beca, Ruth Croxford, Wanrudee Isaranawatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Timothy P. Hanna, Kelvin K.W. Chan   +10 more
doaj   +1 more source

Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non–small-cell Lung Cancer

Frontiers in Pharmacology, 2021
Purpose: The effectiveness of nivolumab plus ipilimumab for advanced non-small cell lung cancer (NSCLC) has been demonstrated. Decisions have to be made about allocating healthcare resources.
Xuezhi Hao, Aizong Shen, Bin Wu
doaj   +1 more source

Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Frontiers in Oncology, 2014
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable ...
Anna M. Leung, Agnes Fermin Lee, Junko eOzao-Choy, Romela Irene Ramos, Omid eHamid, Steven J. O'Day, Myung eShin-Sim, Donald L. Morton, Mark B. Faries, Peter A. Sieling, Delphine J Lee   +10 more
doaj   +1 more source

Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Health and Quality of Life Outcomes, 2012
Background In an international, randomized Phase III trial ipilimumab demonstrated a significant overall survival benefit in previously treated advanced melanoma patients.
Revicki Dennis A, van den Eertwegh Alfons JM, Lorigan Paul, Lebbe Celeste, Linette Gerald, Ottensmeier Christian H, Safikhani Shima, Messina Marianne, Hoos Axel, Wagner Samuel, Kotapati Srividya   +10 more
doaj   +1 more source